What is Cour?
COUR Pharma is at the forefront of developing first-in-class antigen-specific immune tolerance therapies designed to address a wide spectrum of autoimmune diseases. The company's core innovation lies in its proprietary nanoparticle platform, engineered to encapsulate disease-specific antigens. These nanoparticles mimic the anti-inflammatory properties of apoptotic cells, thereby reprogramming the immune system to establish tolerance. Clinical and preclinical data have shown promising results, indicating the potential of COUR's product candidates to offer a new therapeutic paradigm for conditions characterized by immune system dysregulation.
How much funding has Cour raised?
Cour has raised a total of $185M across 3 funding rounds:
Unspecified
$30M
Series A
$105M
Series B
$50M
Unspecified (2022): $30M with participation from Alpha Wave Ventures
Series A (2024): $105M led by Alpha Wave Global and Lumira Ventures
Series B (2026): $50M supported by Roche, Pfizer, Alpha Wave Global, Lumira Ventures, Sanofi, Angelini Ventures, and JDRF T1D Fund
Key Investors in Cour
Alpha Wave Global
Alpha Wave Global is an investment firm that aims to create uncorrelated return streams in public markets and invest in best-in-class venture and growth-stage companies in private markets, endeavoring to be helpful, long-term partners to founders.
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech, biotherapeutics, and medical devices.
Roche
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions, focusing on oncology, immunology, and other key therapeutic areas.
What's next for Cour?
The substantial enterprise-level capital infusion, highlighted by the recent strategic investment, positions COUR Pharma for a critical phase of growth and clinical advancement. This financing is anticipated to fuel the progression of its product candidates through rigorous clinical trials, potentially expanding its therapeutic pipeline and market reach. The company's focus on addressing the root cause of autoimmunity through immune tolerance suggests a long-term strategy aimed at creating durable treatment options. Future developments will likely involve further validation of its platform's efficacy and safety, paving the way for potential regulatory submissions and market entry.
See full Cour company page
